Just a thought last night - last year, Viradx and Febridx generated $300,000 in revenue for the year.
They indicated in the Webinar on their commercial operations update that they had already made $150,000 in sales on Febridx and Viradx in two weeks since its US launch.
For the upcoming quarterly if the same sales level across UK/Europe occurs and the US sales continues even that trend, we could clearly see solid uptake of the product? $75,000 a quarter in UK sales? $150,000+ US sales a quarter?
At least $1Million+ a year in product sales?
Financial Year could be presented with circa $22Million in revenues if the Hologic payments are received in this FY? Less circa $10M in costs (per last years annual costs) this FY they are walking away circa $10Million in net profits to move forward on further expansion?
Add to My Watchlist
What is My Watchlist?
